Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral L19IL2/L19TNF in High-Risk Non-Melanoma Skin Cancer
NCT04362722Phase 2Recruiting
- Sponsor
- Philogen
- Start
- Sep 2020
- Primary completion
- Sep 2024
- Modality
- Antibody Fragments, Immunomodulatory ADCs, Cytokines & Interferons
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of darleukin and onfekafusp alfa in basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), sponsored by Philogen. Primary endpoints: Complete Response at Day 36 and Partial Response at Day 36. Started Sep 2020; status: recruiting.
02
Drugs
darleukinonfekafusp alfa
03
Conditions
basal cell carcinoma (BCC)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04362722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04362722.